Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2024-2036. Allosteric modulators are substances that bind to a receptor to change the receptor's response to stimulus. Positive allosteric modulators function to facilitate agonist-mediated response. The growth of the market can be attributed to the increasing prevalence of mental disorders, such as, dementia, schizophrenia, and others, as positive allosteric modulators are used as a novel treatment approach for the patients. Positive allosteric modulators can be provided to the patients in combination with their currently approved anti-AD drugs, to improve the efficacy of the drugs. The growing cases of Alzheimer’s disease is anticipated to primarily drive the market growth. As per the data by the World Health Organization (WHO), 55 million people live with dementia worldwide, as of 2020, and there are nearly 10 million new cases every year. Out of these 60-70% cases are of Alzheimer’s disease. Moreover, allosteric modulators are also used for medical research and development of new drugs. As per the data by the World Bank, 9.858% of the global gross domestic product (GDP) was spent on healthcare, while research and development expenditure amounted to 2.203% of the GDP in 2018.
Growth Drivers
Challenges
The market is segmented by disease type into Parkinson’s disease, schizophrenia, Alzheimer’s disease, and others out of which, the Alzheimer’s disease segment is anticipated to hold a substantial share in the global positive allosteric modulators market over the forecast period on account of high prevalence of the disorder across the globe. Meanwhile, the Parkinson’s disease segment is also estimated to hold a notable size in the market during the forecast period, owing to the ongoing growth in the cases of the disease. According to the statistics by the Parkinson’s Foundation, more than 10 million people are living with this disorder globally.
Our in-depth analysis of the global positive allosteric modulators market includes the following segments:
|
By Disease Type |
|
|
By Drug Type |
|
|
By End User |
|
On the basis of geographical analysis, the global positive allosteric modulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is poised to dominate majority revenue share by 2036, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.
The positive allosteric modulators market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the higher health awareness amongst the population, along with easy access of quality healthcare in the developed nations, such as, the United States. Moreover, the higher investment in the R&D activities in the region is further expected to boost the market growth. As per the World Bank data, 2.734% of GDP of North America was spend for R&D activities in 2018.
February 16, 2022: Acadia Pharmaceuticals Inc. announced the FDA submission of supplemental New Drug Application (sNDA) for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
June 11, 2020: Interim HealthCare Inc., launched a free dementia caregiver’s guide for homecare for patients living with dementia or Alzheimer’s disease.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?